EZH2 and neoplasm: In DIPG (H3K27M mutation), the use of EZH2 resulted in decreased cancer cell invasion, increased microglial phagocytosis, and tumor cell death, but not tumor cells per se contribute to the observed tumor repression after EZH2 inhibition, but rather the induced transition of microglia to an antitumoral phenotype [100].